Open an account

Bionano Genomics

BNGO · NASDAQ

$1.25+$0.025 (+2.05%)TodayMarket closed ·
Prev close $1.22

BNGO analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy1
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 4 analysts

Average $5.10 (+309.6% upside)

Low
$4.04
Now
$1.25
High
$6.30

Upgrades and downgrades

The latest rating actions, newest first

BNGO analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Apr 13, 2026MaintainsBuy
HC Wainwright & Co.Nov 24, 2025MaintainsBuy

The case for and against

Updated May 12, 2026

Bull case

Bionano Genomics is set to see significant revenue growth in the coming years, driven by increased utilization of its optical genome mapping (OGM) technology across multiple industries including hematologic malignancies, constitutional genetics, and cell and gene therapy quality control. With a strong cash position and signs of expanding utilization in new regions, the company is well positioned to capitalize on its innovative technology. Risks include potential lower-than-projected market uptake and utilization, as well as potential need for additional capital. We reiterate a Buy rating and adjust our 12-month price target to $6 from $7 per share, using a conservative EV/Revenue of 1.5x for projected sales of $2.87 per share for FY2026.

Bear case

Bionano Genomics is showcasing its growing body of research and scaling high-volume solutions at the sold-out 2026 Bionano Symposium, highlighting OGM's ability to detect complex genomic rearrangements that traditional methods often miss. This is supported by published studies showing high concordance and superior detection of structural variants in various types of cancer, indicating potential for a broader application beyond liquid tumors. However, the company's financials show a cash runway only until 2Q26 and potential need for additional capital in the next 12 months. Despite the recent establishment of Category I CPT codes and multiple publications highlighting OGM's utility, the future growth and widespread adoption of OGM remains uncertain, leading to a negative outlook for the stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.